<?xml version="1.0" encoding="UTF-8"?>
<results title="country">
 <result pre="(months) Introduction ATrynÂ©, Laboratoire Francais du Fractionnement et des Biotechnologies," exact="France" post="(antithrombin alfa) Off-label use Spontaneous reports 137 RotarixÂ©, GlaxoSmithKline"/>
 <result pre="alfa) Off-label use Spontaneous reports 137 RotarixÂ©, GlaxoSmithKline Biologicals S.A.," exact="Belgium" post="(human rotavirus, live attenuated) Administration error (accidental parenteral instead"/>
 <result pre="Spontaneous reports 63 CubicinÂ©, Merck Sharp &amp;amp; Dohme B.V., The" exact="Netherlands" post="(daptomycin) Skeletal muscle toxicity Clinical trials Non-clinical studies 118"/>
 <result pre="118 Reduced susceptibility in Staphylococcus aureus OptimarkÂ©, Mallinckrodt Deutschland GmbH," exact="France" post="(gadoversetamide) Nephrogenic systemic fibrosis Clinical trials Non-clinical studies Spontaneous"/>
 <result pre="Non-clinical studies Spontaneous reports 37 VectibixÂ©, Amgen Europe B.V., The" exact="Netherlands" post="(panitumumab) Lack of response and negative effects in combination"/>
 <result pre="mutant KRAS tumours Clinical trials 40 EvicelÂ©, Omrix Biopharmaceuticals N.V.," exact="Belgium" post="(human fibrinogen/human thrombin) Air or gas embolism Spontaneous reports"/>
 <result pre="or gas embolism Spontaneous reports 23 EffentoraÂ©, Teva B.V., The" exact="Netherlands" post="(fentanyl) Misuse, abuse and diversion Spontaneous reports 21 Use"/>
 <result pre="maintenance opioid therapy Unintended (accidental) exposure PandemrixÂ©, GlaxoSmithKline Biologicals S.A.," exact="Belgium" post="[split influenza virus inactivated, containing antigen equivalent to A/California/07/2009"/>
 <result pre="vial Contamination of multiple-dose vials PradaxaÂ©, Boehringer Ingelheim International GmbH," exact="Germany" post="(dabigatran etexilate mesilate) Haemorrhage Clinical trials 74 VprivÂ©, Shire"/>
 <result pre="(dabigatran etexilate mesilate) Haemorrhage Clinical trials 74 VprivÂ©, Shire Pharmaceuticals" exact="Ireland" post="Ltd, Ireland (velaglucerase alfa) Infusion-related reactions Observational studies 71"/>
 <result pre="mesilate) Haemorrhage Clinical trials 74 VprivÂ©, Shire Pharmaceuticals Ireland Ltd," exact="Ireland" post="(velaglucerase alfa) Infusion-related reactions Observational studies 71 ProliaÂ©, Amgen"/>
 <result pre="Infusion-related reactions Observational studies 71 ProliaÂ©, Amgen Europe B.V., The" exact="Netherlands" post="(denosumab) Osteonecrosis of the jaw Clinical trials Observational studies"/>
 <result pre="trials Observational studies Spontaneous reports 60 EliquisÂ©, Bristol-Myers Squibb/Pfizer EEIG," exact="Ireland" post="(apixaban) Bleeding Clinical trials 17 Severe renal or hepatic"/>
 <result pre="or hepatic impairment Liver injury XgevaÂ©, Amgen Europe B.V., The" exact="Netherlands" post="(denosumab) Osteonecrosis of the jaw Clinical trials Observational studies"/>
 <result pre="trials Observational studies Spontaneous reports 46 RiensoÂ©, Takeda Pharma A/S," exact="Denmark" post="(ferumoxytol) Hypersensitivity Spontaneous reports 26 Discontinuation Hirobriz BreezhalerÂ©, Novartis"/>
 <result pre="Hypersensitivity Spontaneous reports 26 Discontinuation Hirobriz BreezhalerÂ©, Novartis Europharm Limited," exact="Ireland" post="(indacaterol maleate) Off-label use Observational studies 93 RenvelaÂ©, Genzyme"/>
 <result pre="Off-label use Observational studies 93 RenvelaÂ©, Genzyme Europe BV, The" exact="Netherlands" post="(sevelamer carbonate) Arteriovenous fistula site adverse drug reactions Unknown"/>
 <result pre="reactions Unknown 96 Peritonitis Vitamin deficiency RevoladeÂ©, Novartis Europharm Limited," exact="Ireland" post="(eltrombopag olamine) Hepatotoxicity Unknown, considered part of clinical practice"/>
 <result pre="bone marrow reticulin formation Haematological malignancies HyQviaÂ©, Baxalta Innovations GmbH," exact="Austria" post="(human normal immunoglobulin) Safety in pregnant and lactating women"/>
 <result pre="compared to the discontinuation rates reported in literature for the" exact="United States" post="Food and Drug Administrationâ€™s (FDA) Risk Evaluation and Mitigation"/>
 <result pre="minimization measures included in risk management plans reviewed by the" exact="United Kingdom" post="regulatory authorityPharm Med2013271253410.1007/s40290-013-0006-6 7.RubinoAArtimeEA descriptive review of additional risk"/>
</results>
